Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lirilumab - Bristol-Myers Squibb/Innate Pharma

Next Previous
X
Search
Drug Profile

Lirilumab - Bristol-Myers Squibb/Innate Pharma

Alternative Names: Anti-KIR (1-7F9); Anti-KIR monoclonal antibody - Innate Pharma; BMS-986015; IPH-21; IPH-2101; IPH-2102; NN 1975; ONO-4483

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Innate Pharma; National Cancer Institute (USA); Ono Pharmaceutical; PrECOG; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; KIR receptor antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bladder cancer
  • Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Head and neck cancer; Hepatitis C; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Smoldering multiple myeloma; Solid tumours

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, First-line therapy, Neoadjuvant therapy) in USA (IV, Infusion)
  • 02 Jan 2023 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV)
  • 02 Jan 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top